Annalisa Morgan, MD, discusses the upcoming Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting and is especially interested in optimizing care for patients with multiple sclerosis, focusing on disease-modifying therapies (DMTs). The meeting will delve into two approaches: (1) starting with low- and moderate-efficacy DMTs and escalating on the basis of disease progression; or (2) using high-efficacy therapies from the start.
Discussions will also explore when to switch therapies and considerations for discontinuation, especially regarding anti-CD20 therapies. In addition, there's anticipation for data from ongoing trials like TREAT-MS and DELIVER-MS. Other topics include adjusting treatment regimens and exploring DMT options for pediatric MS. The meeting will also cover related conditions like NMOSD and MOGAD.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: CMSC 2024: Optimizing Multiple Sclerosis Care - Medscape - May 24, 2024.
Comments